Meinuohua (603538.SH): The oral immediate-release formulation of alogliptin is expected to be selected for national centralized drug procurement.

According to the Zhitong Finance APP, Meinuohua (603538.SH) announced that its wholly-owned subsidiary Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd. (referred to as "Meinuohua Tiankang") recently participated in the twelfth national centralized procurement organized by the National Joint Procurement Office. The oral immediate-release formulation of Alogliptin is expected to be selected in this centralized procurement.